How Daiichi Sankyo Is Dominating TNBC & Immunotherapy Markets for 10‑Year Growth
Explore how Daiichi Sankyo’s oncology and immunotherapy strategy drives 10‑year NPV of $2.5 billion, tackles TNBC patent cliffs, and targets M&A for growth.
4 minutes to read









